EFFECT OF LISINOPRIL ON BLOOD PRESSURE AND CEREBROVASCULAR REACTIVITY IN HYPERTENSIVE PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.29001/2073-8552-2017-32-1-23-28
Abstract
Aim: To investigate the effects of lisinopril on blood pressure and cerebrovascular reactivity (CVR) in patients with arterial hypertension (AH) and rheumatoid arthritis (RA). Materials and Methods. Fifteen patients with AH and RA (age of 61 (52; 64) years; blood pressure (BP) of 147.0 (142; 156)/87.0 (82; 90) mmHg) received lisinopril during a sixmonth open controlled study. Ambulatory BP monitoring and evaluation of CVR were performed twice: initially and at the end of the study. CVR was evaluated using transcranial Doppler ultrasound (TCD) of the middle cerebral arteries (MCA) in hyperoxia and hypercapnia. Results. Treatment with Lisinopril significantly decreased CVR parameters in hyperoxia test as follows: the MCA coefficient of blood flow velocity change and the reactivity index significantly decreased by –28.6% (–39.32; 2.90) (р=0.037) and by –39% (“77; 7) (р=0.010), respectively, after lisinopril treatment. Conclusions. Lisinopril exerted a significant antihypertensive effect and improved CVR during hyperoxia in patients with AH and RA.
About the Authors
O. L. Sarkisova
Siberian State Medical University
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
N. V. Rebrova
Siberian State Medical University
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
T. M. Ripp
Siberian State Medical University
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
I. I. Bogomolova
Siberian State Medical University
Russian Federation
Russian Federation
E. A. Anisimova
Siberian State Medical University
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
V. F. Mordovin
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
R. S. Karpov
Siberian State Medical University
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике // Науч.-практ. ревматол. – 2014. – Т. 52(4). – С. 362–365.
2. Radner H., Yoshida K., Solomon D.H. Multimorbidity and rheumatic conditions – enhancing the concept of comorbidity // Nat. Rev. Rheumatol. – 2014. – Vol. 10. – Р. 252– 256.
3. Ranganath V.K., Maranian P., Elashoff D.A. et al. Comorbidity are associated with poorer outcome in community patients with rheumatoid arthritis // Rheumatology. – 2013. – Vol. 52. – Р. 1809–1817.
4. Hyrich K., Symmons D., Watson K. et al. BSRBR Control Centre Consortium on behalf of the British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national register // Ann. Rheum. Dis. – 2006. – Vol. 65. – Р. 895–898.
5. Briggs A.M., March L., Lassere M. et al. Baseline comorbidies in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian Rheumatology Association Database // Int. J. Rheum. – 2009. – Article ID 861481.
6. Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin // Rheumatology. – 2005. – Vol. 44. – Р. 1473–1482.
7. Новикова Д.С., Попкова Т.В., Насонов Е.Л. Артериальная гипертензия при ревматоидном артрите // Науч.-практ. ревматол. – 2011. – № 50(3). – С. 52–68.
8. Рипп Т.М., Мордовин В.Ф., Рипп Е.Г. и др. Комплексная оценка параметров цереброваскулярной реактивности // Сиб. мед. журн. (Томск). – 2016. – Т. 31, № 1. – С. 12–17.
9. Wbelton A., White W.B., Bello A.E. et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis // Am. J. Cardiol. – 2002. – Vol. 90. – P. 959–963.
10. Кисляк О.А. Ингибитор АПФ лизиноприл в лечении пожилых пациентов с изолированной систолической и систоло-диастолической артериальной гипертензией // Леч. дело. – 2007. – № 2. – С. 43–50.
11. Реброва Н.В., Анисимова Е.А., Рипп Т.М. и др. Влияние валсартана на цереброваскулярную реактивность у больных артериальной гипертонией в сочетании с ревматоидным артритом // Артериальная гипертония 2016: итоги и перспективы: тезисы XII всероссийского конгресса. – М., 2016. – C. 15.
12. Рипп Т.М., Мордовин В.Ф., Карпов Р.С. Нарушение процессов цереброваскулярной регуляции и когнитивной функции у пациентов с артериальной гипертонией, возможности коррекции антагонистом рецепторов к ангиотензину II // Артер. гипертензия. – 2010. – № 16(5). – С. 504–510.
Review
For citations:
Sarkisova O.L., Rebrova N.V., Ripp T.M., Bogomolova I.I., Anisimova E.A., Mordovin V.F., Karpov R.S. EFFECT OF LISINOPRIL ON BLOOD PRESSURE AND CEREBROVASCULAR REACTIVITY IN HYPERTENSIVE PATIENTS WITH RHEUMATOID ARTHRITIS. Siberian Journal of Clinical and Experimental Medicine. 2017;32(1):23-28. (In Russ.) https://doi.org/10.29001/2073-8552-2017-32-1-23-28
Views:
486
.png)
Email this article 